Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesLong-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: An observational study
Epilepsia, 07/01/09
Cho YJ et al. – Low-dose and slow-dose escalation of topiramate (TPM) in add-on therapy for pts with refractory partial epilepsy is effective and well tolerated in long-term, individualized clinical practice.
Methods- Retrospective, single-center, long-term observational study of long-term efficacy and tolerability of TPM as add-on therapy in pts with refractory partial epilepsy
- Subjects: Pts fulfilling Berg medical intractability criteria with newly prescribed TPM as add-on therapy between January 2000-June 2002
- Usual starting dosage of TPM: 50 mg/day
- Optimal-dose adjustments based on individual clinical responses
- Analysis of efficacy and tolerability every year during 5-yr follow-up in intention-to-treat (ITT) population
- Of 125 study pts, 107 (85.6%) followed for 5 yrs
- Retention rate: 87.2% at 1 yr; 64% at 5 yrs
- At end of 5 yrs, 69.0% median seizure frequency reduction rate; 43.2% responder rate in ITT population
- Cumulative seizure-free rate (SFR): 30.4%
- Terminal 1-yr SFR: 12.8% in ITT population (20.0% in completers) at 5-yr follow-up
- Adverse events (AEs) in 39.2% of pts, including significant AEs leading to antiepileptic drug (AED) withdrawal in 14.4%
- Most common AEs: anorexia (16.0%), weight loss (10.4%), gastrointestinal symptoms (8.8%)
- Concomitant AEDs reduced in 25.0% of completers
Related Articles
Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo-controlled trials
Epilepsia, 10/29/09
Relevance Score: 80%
Visual Field Loss in Patients with Refractory Partial Epilepsy Treated with Vigabatrin: Final Results from an Open-Label, Observational, Multicentre Study
CNS Drugs, 10/28/09
Relevance Score: 79%
Treatment of refractory complex partial seizures: role of vigabatrin
Neuropsychiatric Disease and Treatment, 10/08/09
Relevance Score: 79%
Contralateral MRI abnormalities in candidates for hemispherectomy for refractory epilepsy
Epilepsia, 10/21/09
Relevance Score: 67%
Pathologic cardiac repolarization in pharmacoresistant epilepsy and its potential role in sudden unexpected death in epilepsy: A case–control study
Epilepsia, 10/21/09
Relevance Score: 66%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Probable levetiracetam-associated depression in the elderly: Two case reports
The American Journal of Geriatric Pharmacotherapy, 12/18/09
Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry in six countries
Current Medical Research and Opinion, 12/18/09
Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders
Phytotherapy Research, 12/18/09
Today in Seizure...keeping you current
Receive free subspecialty "5-minute updates" via email
Stimulation threshold potentials of intraoperative cortical motor mapping using monopolar trains of five in pediatric epilepsy surgery
Child's Nervous System, 12/18/09
Probable levetiracetam-associated depression in the elderly: Two case reports
The American Journal of Geriatric Pharmacotherapy, 12/18/09
Changing patterns of antiepileptic drug use in pregnant Australian women
Acta Neurologica Scandinavica, 12/18/09
Sponsor
Article Search
Sponsor
Sponsor